

Jenny Han

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11990333/jenny-han-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27 papers	3,584 citations	16 h-index	27 g-index
27 ext. papers	3,856 ext. citations	6.5 avg, IF	4.73 L-index

#	Paper	IF	Citations
27	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 393-403	6.7	30
26	Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 223-230	3.3	13
25	Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2018 , 9, 551-564	3.6	5
24	Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 672-681	6.7	38
23	Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c $\geq 10.0\%$: Two pooled analyses including 20 randomised controlled trials. <i>International Journal of Clinical Practice</i> , 2017 , 71, e13029	2.9	3
22	Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1415-1422	3.2	7
21	Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2017 , 41, 69-74	5	12
20	Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1793-1797	6.7	3
19	Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. <i>Diabetes Technology and Therapeutics</i> , 2016 , 18, 677-686	8.1	32
18	Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data. <i>Clinical Therapeutics</i> , 2016 , 38, 1464-1473	3.5	5
17	Disabled homolog 2 controls macrophage phenotypic polarization and adipose tissue inflammation. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1311-22	15.9	43
16	Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. <i>Current Medical Research and Opinion</i> , 2014 , 30, 1209-18	2.5	7
15	Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 464-73	18.1	126
14	Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. <i>Cardiovascular Diabetology</i> , 2013 , 12, 48	8.7	15
13	Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data. <i>Postgraduate Medicine</i> , 2013 , 125, 58-67	3.7	5
12	Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. <i>Postgraduate Medicine</i> , 2013 , 125, 47-57	3.7	62
11	Exenatide at therapeutic and suprathreshold concentrations does not prolong the QTc interval in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 979-89	3.8	31

10	Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. <i>Vascular Health and Risk Management</i> , 2012 , 8, 255-64	4.4	20
9	Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2012 , 5, 29-41	3.4	33
8	Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. <i>Clinical Therapeutics</i> , 2012 , 34, 1247-1258.e22	3.5	200
7	Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary. <i>Clinical Therapeutics</i> , 2012 , 34, 1301-13	3.5	3
6	Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. <i>BMC Endocrine Disorders</i> , 2011 , 11, 9	3.3	56
5	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2011 , 10, 22	8.7	124
4	Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. <i>Postgraduate Medicine</i> , 2010 , 122, 118-28	3.7	26
3	Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. <i>Circulation Research</i> , 2010 , 107, 737-46	15.7	366
2	Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. <i>Diabetes Care</i> , 2005 , 28, 1092-100	14.6	1231
1	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. <i>Diabetes Care</i> , 2004 , 27, 2628-35	14.6	1088